<DOC>
	<DOCNO>NCT02883426</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity H3N2v MN 2010/AA ca live attenuated influenza vaccine ( H3N2v LAIV ) healthy child adult , 6 26 year old .</brief_summary>
	<brief_title>Evaluating Safety Immunogenicity Live Attenuated Virus Vaccine Prevent Influenza H3N2v Disease</brief_title>
	<detailed_description>The potential widespread human disease due H3N2v influenza viruses considerable . Infection virus would likely impact young child . This study evaluate safety immunogenicity H3N2v MN 2010/AA ca live attenuated influenza vaccine ( H3N2v LAIV ) healthy child adult , 6 26 year old . The study enroll participant sequentially four group : Group 1 include H3N2v seronegative adult age 18-26 year ; Group 2 include H3N2v seropositive adolescent age 13-17 year ; Group 3 include H3N2v seronegative adolescent age 13-17 year ; Group 4 include child age 6 12 year , screen H3N2v serostatus . At study entry ( Day 0 ) , participant Group 1 receive one dose H3N2v LAIV . Participants Groups 2 , 3 , 4 randomly assign receive two dos either H3N2v LAIV placebo , receive first dose Day 0 second dose Day 28 . On Day 84 , participant receive one dose H3N2v IIV ( inactivated booster vaccine ) . Participants attend several additional study visit Day 180 . These visit may include physical examination ; respiratory examination ; collection blood , urine , nasal fluid .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males nonpregnant female 6 26 year age inclusive . For child , presence adult caregiver good health able understand carry requirement General good health , without significant medical illness , physical examination finding , significant laboratory abnormality determine investigator . Agree storage blood specimens future research . Available duration trial . Willingness participate study evidence sign informed consent document . Verbal assent obtain minor 6 12 year age sign assent obtain minor 13 old . Female subject childbearing potential must agree use effective birth control method duration study ( e.g. , pharmacologic contraceptive include oral , parenteral , transcutaneous delivery ; condom spermicide ; diaphragm spermicide ; intrauterine device ; abstinence heterosexual intercourse , surgical sterilization ) . Anticipated direct routine [ e.g . weekly frequent ] contact individual younger designate age group study result household contact , occupation , participation day care individual . Pregnancy determine positive urine serum human choriogonadotropin ( βHCG ) test . Currently breastfeed . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history physical examination . Behavioral cognitive impairment psychiatric disease , opinion investigator , affect ability subject understand cooperate study protocol . Other condition , opinion investigator , would jeopardize safety right subject participate trial would render subject unable comply protocol . History anaphylaxis . Allergy oseltamivir determine subject report . Current diagnosis asthma reactive airway disease ( within past 2 year ) . Use aspirin salicylatecontaining medication within 28 day prior randomization expect receipt 28 day final vaccination . History GuillainBarré Syndrome . Known history HIV , hepatitis C , active hepatitis B infection . Known immunodeficiency syndrome . Use corticosteroid ( exclude topical preparation ) immunosuppressive drug within 30 day prior vaccination . Receipt live vaccine within 4 week kill vaccine within 2 week prior study vaccination . Receipt blood bloodderived product ( include immunoglobulin ) within 6 month prior study vaccination . Travel Southern Hemisphere within 14 day prior study vaccination . Travel cruise ship within 14 day prior study vaccination . Receipt another investigational vaccine drug within 30 day prior study vaccination . Allergy egg egg product , gentamicin , gelatin . Chronic use intranasal medication .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>H3N2v Influenza Viruses</keyword>
</DOC>